This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
One of these “new” strategies that has grown in popularity over the past decade is the concept of “roll-ups” (also sometimes called “platform acquisition strategies”). This begs an important question: why do roll-ups receive a higher value than smaller acquisition targets? and thus receive volume discounts with better pricing.
Some of the tax provisions contained in the legislation, including the 1% excise tax on certain stock buybacks, may impact special purpose acquisition companies (SPACs) at key points in their life cycle. Notable public deals. Amazon to Acquire One Medical for $3.9 Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals.
according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. Similarly, PE-backed platform companies have undergone substantial consolidation through mergers and acquisitions.” Founded in 2007, publicly-traded TOI provides care to about 1.8
A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 billion acquisition of The Medicines Company. Year of the Life Sciences Mega-Deals.
But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.
1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.
The year started off with a bang, with mega-deals such as Microsoft’s pending $69 billion acquisition of Activision Blizzard, Elon Musk’s $44 billion acquisition of Twitter and Broadcom’s pending $61 billion acquisition of VMware inked in quick succession. Tech M&A in 2022 was a tale of two halves.
McKessons acquisition of PRISM Vision Group is an important milestone for private equitys investments in optometry practices. McKesson, a public company with approximately $76 billion in market value, will purchase an 80% interest in PRISM for approximately $850M.
billion acquisition of Alpine Immune; by contrast, there were eight US biotech acquisitions exceeding $5 billion in 2023. 2024 saw companies focusing on internal research and development, innovative partnerships, and targeted bolt-on asset acquisitions to bolster their pipelines. from 2023. [1]
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content